Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference
Jun. 14, 2018
DURHAM, N.C.--(BUSINESS WIRE)--Jun 14, 2018--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the JMP Securities 2018 Life Science Conference on Thursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
The fireside chat will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Aerie's first product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA) in December 2017 and was launched in the U.S. market in April 2018. A link to the full product label is available on the Aerie website at http://investors.aeriepharma.com. Aerie’s advanced-stage product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa ® and widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1. The Roclatan™ NDA submission took place in May 2018. Aerie is also focused on global expansion and the development of additional product candidates and technologies in ophthalmology.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180614005028/en/
CONTACT: Aerie Pharmaceuticals
Tad Heitmann, 949-526-8747
Richard Rubino, 908-947-3540
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Justin Jackson, 212-213-0006
Ami Bavishi, 212-213-0006
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK NORTH CAROLINA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE
SOURCE: Aerie Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 06/14/2018 07:30 AM/DISC: 06/14/2018 07:30 AM